Table 2—

Summary of demographic, background and baseline characteristics of the intent-to-treat population

OmalizumabPlacebo
Subjects n274272
Sex M/F141/133127/145
Race Caucasian/other256/18242/30
Age yrs40.0 (12–76)39.0 (12–72)
Duration of asthma yrs20.3 (2–68)19.1 (1–63)
Smoking status
 Nonsmoker213 (77.7)207 (76.1)
 Exsmoker61 (22.3)65 (23.9)
Daily BDP dose µg769.0 (500–1600)772.1 (200–2000)
Serum total IgE IU·mL−1223.1 (21–785)205.6 (22–814)
FEV1 L2.53 (1.00–5.05)2.52 (0.64–5.05)
FEV1 % pred69.8 (30–112)69.9 (22–109)
FEV1 reversibility %#26.4 (10–86)25.8 (11–103)
Asthma severity
 Moderate214 (78.1)213 (78.3)
 Severe+60 (21.9)59 (21.7)
History of
 Atopic dermatitis24 (8.8)28 (103)
 Seasonal allergic rhinitis183 (66.8)177 (65.1)
 Perennial allergic rhinitis213 (77.7)209 (76.8)
  • Data presented as mean (range) or n (%) unless otherwise stated

  • M: male

  • F: female

  • BDP: beclomethasone dipropionate

  • IgE: immunoglobulin-E

  • FEV1: forced expiratory volume in one second

  • IU: International Units

  • #: Per cent increase in FEV1 from baseline within 30 min of taking 200 µg inhaled salbutamol

  • +: baseline FEV1 ≤65% pred and a mean total symptom score of >4 for the last 14 days of the run-in period